Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MITO END-3: Carboplatin + Paclitaxel versus Carboplatin + Paclitaxel + Avelumab in advanced or recurrent endometrial cancer
2016-004403-31Phase 2Completed
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in endometrial cancer (EC), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Started Jan 2022; status: completed.
02
Drugs
avelumab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2016-004403-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004403-31.